Nova Safo

Can the Iran war end soon enough to avoid worse economic damage here and abroad?

I'm Novosafo for Marketplace.

Many companies have been reluctant to include GLP-1 weight loss drugs in their health benefits.

For one, they cost a lot, and a lot of people want to take them.

Matthew Ray, with a nonpartisan health policy research firm KFF, has been surveying companies about the issue and says that those that do pay for the drugs have found themselves in a pickle.

That's led to a serious math problem, says Luca Maini of Harvard Medical School.

Some companies have even dropped coverage of them altogether.

Overall, only one in five employer-sponsored health plans cover the drugs for weight loss.

Eli Lilly has announced a new initiative trying to address these problems.

Senior Vice President Kevin Hearn says they're offering one transparent price, $450 a month for ZepBound, so that companies can budget better.

Eli Lilly is also partnering with telehealth providers to help companies administer the drugs.

In order to get more of them to conclude that paying for the drugs is cheaper in the long run than the costs associated with obesity.

I'm Novosafo for Marketplace.

The latest tariffs keep higher levies mostly in place for now, despite the Supreme Court's ruling.

The Yale budget lapse as the effective rate on the whole now averages 13.7 percent, down from 16 percent.

The new tariffs are under a statutory authority known as Section 122 that no president has previously invoked, and they must be temporary.

Treasury Secretary Scott Besson told CNN's State of the Union that the administration will likely impose other tariffs under more commonly used authorities.

but those take longer to implement.

I think it's highly likely that those tariffs will rise up and that the 122s could disappear after five months.

There's also the option of asking Congress to enact higher tariffs, but the administration has not signaled any willingness to do so.